SCHEMBL4695367

SCHEMBL4695367

C[Si](C)(C)CCOCn1cnc2c1-c1cc(Cl)ccc1Oc1ccccc1-2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.39
DRD2 P14416 5/20 0.35
DRD4 P21917 5/20 0.35
HRH4 Q9H3N8 5/20 0.35
HRH2 P25021 3/20 0.35
HRH1 P35367 3/20 0.35
ADRB2 P07550 2/20 0.35
CHRM2 P08172 2/20 0.35
CHRM4 P08173 2/20 0.35
HTR1A P08908 2/20 0.35
CHRM5 P08912 2/20 0.35
ADRA2A P08913 2/20 0.35
ADORA3 P0DMS8 2/20 0.35
CHRM1 P11229 2/20 0.35
ADRA2B P18089 2/20 0.35
ADRA2C P18825 2/20 0.35
CHRM3 P20309 2/20 0.35
DRD1 P21728 2/20 0.35
DRD5 P21918 2/20 0.35
SLC6A2 P23975 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4697520 0.96 MAPK1 (0.39) MAPK1DRD2DRD4HRH4HRH2
SCHEMBL4692890 0.89 BRD4 (0.34) BRD4CREBBPCYP1A2CYP2D6LMNA
SCHEMBL4697521 0.83 LMNA (0.39) MAPK1DRD2DRD4HRH4HRH1
SCHEMBL4695913 0.82 LMNA (0.38) MAPK1DRD2DRD4HRH4HRH1
SCHEMBL4696667 0.78 MAPK1 (0.36) MAPK1DRD2DRD4HRH4HRH2
SCHEMBL4696998 0.77 MAPK1 (0.35) MAPK1DRD2DRD4HRH4HRH2
SCHEMBL4688228 0.77 MAPK1 (0.40) MAPK1DRD2DRD4HRH4HRH2
SCHEMBL5436718 0.77 F11 (0.38) MAPK1DRD2DRD4HRH4HRH2
SCHEMBL4076134 0.76 OPRL1 (0.38)
SCHEMBL5225145 0.76 MAPK1 (0.37) MAPK1DRD2DRD4HRH4HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1509528-B1 1,3-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF GLAXOSMITHKLINE ZAGREB (HR) 2008-09-24 EP disclosed
US-7166583-B2 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2007-01-23 US disclosed
US-20050227963-A1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227963-A1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof IL1A, TNF, IL1B MAPK1 161/4885DRD2 1131/4885DRD4 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.